Benitec reports positive interim clinical data for BB-301 in OPMD first subject at 90 days

Benitec Biopharma Inc.

First subject showed improvements in videofluoroscopic swallowing studies and Sydney Swallow Questionnaire at Day 90 vs. pre-dose baseline.
No serious adverse events observed; two subjects had transient Grade 2 GERD that resolved with standard medication.
BB-301 is a gene therapy for OPMD, affecting ~15,000 patients worldwide; has FDA and EMA Orphan Drug designation.
Data from 90-day timepoint demonstrated improvement over initial natural history measurements taken >12 months prior.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.